The Latest Breaking News from Bluebird

The Bluebirds have already seen two people, including the manager Mark Hudson, depart the backroom team this month

It's the watered-down end of a rocks glass, 12 ounces at a time. Hooray?

The Bluebirds are recalling the defender after a fantastic loan stint at Hillsborough

The Bluebirds have placed Mark Hudson in charge on an interim basis following the departure of Steve Morison

Bluebirds icon Peter Whittingham tragically passed away in March 2020 and the heartache is still felt by his family and all who knew him

Bluebird Bio Inc.’s gene therapy for a brain-wasting disease received accelerated approval from U.S. regulators, making it the first treatment of its kind for children living with cerebral adrenoleukodystrophy.

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

For the estimated 1,500 Americans suffering from a blood disorder known as beta thalassemia, the Food and Drug Administration's approval Aug. 17 of the drug Zynteglo was almost unalloyed good news.

The latest Bluebirds news from Cardiff City Stadium

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

The latest Bluebirds news from Cardiff City Stadium